The study was conducted at sites in Kenya and Senegal in healthy adults, children, and infants, and evaluated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health ...

Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases. Read why I rate NKTR stock a ...

Among inpatients at an academic center, serial adjunctive ketamine infusions were no more effective at treating major depression than midazolam, according to a randomized clinical trial published in ...

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...

PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy. Read about what this means for the stock here.

An expert in gout clinical trials questions whether ethical considerations for such trials need updating to emphasize patient choice, dose alterations, and anti-inflammatory prophylaxis.

The biggest stories of the day delivered to your inbox.

The MCU’s Phase 4 released instalments during 2021 and ’22, Phase 5 released during 2023, ’24, and ’25, and Phase 6 will run until 2027. Following this pattern, the MCU’s Phase 7 will likely span ...

Get the latest federal technology news delivered to your inbox. Greg Barbaccia, the federal chief information officer, says that the Office of Management and Budget is backing the General Services ...